Table 1

Patient characteristics

RA
(n=432)
axSpA
(n=240)
Total
(n=672)
Age (years)n=368
58.3±13.1
n=207
47.0±13.2
n=575
54.2±14.2
Gendern=373n=208n=581
 Female276 (74.0%)94 (45.2%)370 (63.7%)
 Male97 (26.0%)114 (54.8%)211 (36.3%)
Professional activityn=424n=237n=661
In employment162 (38.2%)167 (70.5%)329 (49.8%)
 Student2 (0.5%)1 (0.4%)3 (0.5%)
 Unemployed8 (1.9%)19 (8.0%)27 (4.1%)
 Retired201 (47.4%)30 (12.7%)231 (34.9%)
 Other51 (12.0%)20 (8.4%)71 (10.7%)
Education leveln=427n=238n=665
Primary77 (18.0%)11 (4.6%)88 (13.2%)
 Secondary219 (51.3%)134 (56.3%)353 (53.1%)
 Tertiary131 (30.7%)93 (39.1%)224 (33.7%)
Disease duration (years)n=358n=203n=561
13.1±11.413.8±10.613.4±11.1
Disease activityn=427n=236
 DAS282.6±1.2
 BASDAI3.3±2.2
 Physician global assessment of disease activity (NRS)n=419n=232n=651
2.75±2.123.44±2.413.00±2.25
 Patient global assessment of disease activity (NRS)n=382n=216n=598
3.03±2.454.27±2.613.48±2.58
Treatmentsn=326n=238n=564
 None5 (1.5%)7 (2.9%)12 (2.1%)
 Corticosteroids alone6 (1.8%)6 (1.1%)
 NSAIDs alone36 (15.1%)36 (6.4%)
 Synthetic DMARDs ± corticosteroids61 (18.7%)61 (10.8%)
 Synthetic DMARDs ± NSAIDs15 (6.3%)15 (2.7%)
 Biological DMARDs (alone or in combination)252 (77.3%)173 (72.7%)425 (75.4%)
 Other2 (0.6%)7 (2.9%)9 (0.7%)
  • Data are presented as mean values±SD for continuous variables, and as frequency counts (%) for categorical variables.

  • axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS28, 28-item Disease Activity Score; DMARD, disease-modifying antirheumatic drug; NRS, numerical rating scale; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis.